Skip to main content
S&P 5007,696.02+1.68%DOW53,299.35+2.92%NASDAQ25,806.01+1.71%BTC$80,353.00+3.61%ETH$2,423.32+5.73%GOLD$4,073.00+3.37%OIL$88.31-8.10%
Smart Investors Daily
SID Premium
CT

NASDAQ · CTXR

Citius Pharmaceuticals, Inc.

Healthcare · Biotechnology

$0.57

Down-$0.02 (-3.44%)

Updated Nov 4, 2026, 6:57 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
12.96M
P/E ratio
-0.32
Dividend yield
0.00%
52-week range
$0.37 – $1.60
Volume
98.17K
Avg. volume
805.13K

Price performance · CTXR

CTXR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

CTXR closed at $0.57 after 21 trading sessions, up 19.24% for the selected period.

Last close
$0.57
Period change
+19.24%
Period low
$0.37
Period high
$0.57
Daily close
View OHLC price history
CTXR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.56$0.5732$0.5201$0.573298.17K
Nov 2, 2026$0.5284$0.5695$0.52$0.562372.74K
Oct 30, 2026$0.564$0.564$0.5207$0.5231104.67K
Oct 29, 2026$0.525$0.61$0.4843$0.5631403.03K
Oct 28, 2026$0.503$0.55$0.48$0.5411203.19K
Oct 27, 2026$0.442$0.525$0.4075$0.5015525.54K
Oct 26, 2026$0.404$0.47$0.391$0.4493377.89K
Oct 23, 2026$0.377$0.41$0.37$0.4034435.5K
Oct 22, 2026$0.39$0.3906$0.3699$0.3708341.37K
Oct 21, 2026$0.41$0.4125$0.3937$0.3955383.64K
Oct 20, 2026$0.434$0.4363$0.4175$0.4175187.99K
Oct 19, 2026$0.46$0.4691$0.4142$0.4278533.52K
Oct 16, 2026$0.46$0.475$0.46$0.46141.48K
Oct 15, 2026$0.46$0.4869$0.46$0.46305.37K
Oct 14, 2026$0.462$0.47$0.4501$0.465233.62K
Oct 13, 2026$0.481$0.4998$0.46$0.476201.1K
Oct 12, 2026$0.49$0.51$0.48$0.4928119.67K
Oct 9, 2026$0.49$0.5099$0.4802$0.4994144.28K
Oct 8, 2026$0.49$0.5207$0.48$0.4887132.54K
Oct 7, 2026$0.4889$0.51$0.4879$0.5011161.92K
Oct 6, 2026$0.52$0.526$0.48$0.4807420.26K

Latest CTXR news

The latest Smart Investors Daily articles mentioning CTXR.

Stock researchCompany · Overview

CTXR research

Overview

Company profile and research snapshot.

Company profile

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CTXR recent ratings
DateFirmRatingTarget
Mar 11, 2026D. Boral CapitalBuy—
Dec 4, 2025D. Boral CapitalBuy—
Aug 13, 2025D. Boral CapitalBuy—
Jun 30, 2025D. Boral CapitalBuy—
Jun 10, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026.

Yahoo · Oct 12, 2026

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By